News

FDA Approves Dostarlimab for Mismatch Repair Deficient Recurrent or Advanced Endometrial Cancer

02/10/2023

On February 9, 2023, the FDA approved dostarlimab-gxly for adult patients with mismatch repair deficient recurrent or advanced endometrial cancer.

On February 9, 2023, the FDA...

02/10/2023

Oncology

News

Talazoparib Plus Avelumab Demonstrates Clinical Benefit for Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer

10/27/2022

Derek Cowsert ;

Talazoparib and avelumab demonstrated a favorable toxic effect profile and clinical benefit for patients with recurrent mismatch repair proficient endometrial cancer, according to findings from a clinical trial.

Talazoparib and avelumab...

10/27/2022

Oncology

Conference Coverage

Triplet Therapy Improves Response, Demonstrates Acceptable Safety in Recurrent Endometrial Cancer

06/21/2022

Janelle Bradley ;

Treatment with rucaparib, bevacizumab, and atezolizumab is feasible, demonstrating clinically meaningful improvement in response with acceptable safety for patients with recurrent endometrial cancer, according to a phase 2 trial.

Treatment with rucaparib,...

06/21/2022

Oncology

Conference Coverage

Camrelizumab Plus Apatinib Demonstrates Promising Antitumor Activity, Manageable Safety in Endometrial Cancer

06/09/2022

Janelle Bradley ;

In a phase 2 trial, camrelizumab plus apatinib demonstrated promising antitumor activity and manageable safety in patients with advanced or recurrent endometrial cancer that did not respond to first-line therapy.

In a phase 2 trial, camrelizumab...

06/09/2022

Oncology

News

Upfront MGPT Improves Lynch Syndrome Diagnosis in Patients With Endometrial Cancer

05/29/2021

According to data being presented at ASCO 2021, the use of upfront MGPT in patients with endometrial cancer has improved the detection of Lynch syndrome among this population.

According to data being...

05/29/2021

Oncology

News

Experts Discourage Intensive Follow-Up of Patients Treated for Endometrial Cancer

05/25/2021

According to study findings presented at the 2021 ASCO Annual Meeting, the use of frequent routine imaging and laboratory exams in patients treated for endometrial cancer should be discouraged.

According to study findings...

05/25/2021

Oncology

News

Endometrial Cancer Incidence Tied to Obesity in Young Adult Women

05/25/2021

At the 2021 ASCO Annual Meeting, researchers presented data from a study evaluating trends in endometrial cancer incidence and its relationship to obesity in the United States.

At the 2021 ASCO Annual Meeting,...

05/25/2021

Oncology

News

FDA Approves Dostarlimab-gxly for Adults With dMMR Endometrial Cancer

04/22/2021

Hina M. Porcelli ;

The FDA has approved dostarlimab-gxly for the treatment of adults with dMMR recurrent or advanced endometrial cancer that progressed during or after a platinum-containing therapy.

The FDA has approved...

04/22/2021

Oncology

Conference Insider

No Survival Benefit With Adjuvant Chemo or RT for Endometrial Cancer

03/30/2021

Post-operative systemic chemo and RT did not improve OS in high-risk patients with stage I endometrial cancer, according to Rachelle Findley, MD, et al.

Post-operative systemic chemo...

03/30/2021

Oncology

News

Using Postmenopausal Bleeding to Detect Endometrial Cancer

09/19/2020

Evaluating women for postmenopausal bleeding aids in the early detection of, and implementation of prevention strategies for, endometrial cancer.

Evaluating women for...

09/19/2020

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology